Novel PET Radiotracer 68Ga-FZ-NR-1 Successfully Identifies Nectin-4 Biomarker in Triple-Negative Breast Cancer Patients
核心洞察
Researchers developed and tested three Nectin-4 (搜索)-targeted PET radiotracers, with 68Ga-FZ-NR-1 (搜索) showing the highest targeting efficacy in preclinical studies.
First-in-human study of 68Ga-FZ-NR-1 (搜索) PET/CT in nine TNBC (搜索) patients successfully identified tumors, with positive lesions corresponding to areas of high Nectin-4 (搜索) expression confirmed by biopsy.
The radiotracer demonstrated strong hydrophilicity (log D7.4 = −3.55 ± 0.10) and high specificity for Nectin-4 (搜索) (Kd = 2.81 nM) with significantly higher accumulation in Nectin-4-positive tumor cells.
Researchers at Fudan University Shanghai Cancer Center have successfully developed and clinically validated a novel PET radiotracer that can effectively visualize Nectin-4 (搜索), an emerging biomarker highly expressed in triple-negative breast cancer (搜索) (TNBC (搜索)). The study, published in The Journal of Nuclear Medicine, represents a significant advancement in precision imaging for one of the most aggressive breast cancer (搜索) subtypes.
TNBC (搜索) accounts for 15-20 percent of breast cancer (搜索) cases and presents unique clinical challenges due to its invasive nature and poor prognosis, with a five-year survival rate of approximately 40 percent. The disease is characterized by significant heterogeneity and high recurrence rates, making effective treatment particularly difficult.
Development and Optimization of Nectin-4-Targeted Radiotracers
The research team developed three different Nectin-4 (搜索)-targeted radiotracers: 68Ga-FZ-NR-1 (搜索), 68Ga-FZ-NR-2 (搜索), and 68Ga-FZ-NR-3 (搜索). After comprehensive preclinical evaluation assessing targeting ability and specificity both in vitro and in vivo, as well as in murine tumor models, 68Ga-FZ-NR-1 emerged as the most promising candidate.
The selected radiotracer demonstrates exceptional binding characteristics, with strong hydrophilicity (log D7.4 = −3.55 ± 0.10) and high specificity for Nectin-4 (搜索) (Kd = 2.81 nM). In early in vitro studies, the probe showed significantly higher accumulation in Nectin-4-positive tumor cells (MDA-MB-468) compared to negative tumor cells (MDA-MB-231).
Preclinical studies in mice xenografted with MDA-MB-468 tumors revealed significantly higher tumor uptake (3.53 ± 0.33 %ID/g) compared to Nectin-4 (搜索)-negative tumors (2.4 ± 0.4 %ID/g) and blocking groups (2.4 ± 0.18 %ID/g). Importantly, toxicity tests performed on mice showed no relevant side effects even at high doses, as confirmed by stable body weight maintenance, normal blood parameters, and absence of alterations in major organs.
First-in-Human Clinical Validation
Following successful preclinical screening, the research team conducted a first-in-human study involving nine TNBC (搜索) patients. 68Ga-FZ-NR-1 (搜索) PET/CT imaging was performed, with positive lesions subsequently biopsied and analyzed by immunohistochemistry to determine Nectin-4 (搜索) expression levels.
The clinical results demonstrated that 68Ga-FZ-NR-1 (搜索) PET/CT effectively identified tumors in study participants, with findings confirmed by 18F-FDG PET/CT. Crucially, biopsy samples revealed that positive lesions identified by 68Ga-FZ-NR-1 PET/CT corresponded directly to areas of high Nectin-4 (搜索) expression, validating the tracer's specificity and clinical utility.
Clinical Significance and Future Implications
"The Nectin-4 (搜索) biomarker is highly expressed in TNBC (搜索), but effective, targeted imaging tools have been notably absent," stated Shaoli Song, PhD, director of nuclear medicine at Fudan University Shanghai Cancer Center. "To address this critical gap in the field, my colleagues and I developed a series of Nectin-4-targeted radiotracers and evaluated them for efficacy in detecting Nectin-4 in TNBC."
The clinical validation of 68Ga-FZ-NR-1 (搜索) addresses a significant unmet need in TNBC (搜索) management. Current imaging approaches lack the specificity to accurately assess Nectin-4 (搜索) expression, which is crucial for treatment selection and monitoring, particularly given the emergence of Nectin-4-targeted therapies like enfortumab vedotin.
Song emphasized the transformative potential of this development: "The significance of this research lies in its potential to revolutionize the diagnostic landscape for TNBC (搜索) patients. With the introduction of 68Ga-FZ-NR-1 (搜索), we are now able to detect tumors with greater precision and provide patients with more reliable diagnostic information. This advancement has the potential to improve treatment outcomes by enabling more accurate disease assessment and personalized therapeutic strategies."
Broader Impact on Precision Oncology
The successful clinical translation of 68Ga-FZ-NR-1 (搜索) represents part of a broader movement toward precision imaging in oncology. Unlike metabolic tracers such as 18F-FDG, which lack specificity for particular tumor markers, Nectin-4 (搜索)-targeted radiotracers enable visualization of specific therapeutic targets throughout the body, facilitating personalized treatment approaches.
This development is particularly significant given the challenges associated with Nectin-4 (搜索)-targeted therapy resistance. The ability to visualize Nectin-4 expression loss in real-time could enable timely treatment modifications, potentially improving patient response rates while reducing healthcare costs.
The research team anticipates that this work will stimulate further investigation into Nectin-4 (搜索)-targeted imaging agents. "Ultimately, this could enhance the diagnostic value of nuclear medicine not only for TNBC (搜索), but also for other cancers," Song noted, highlighting the broader applicability of this approach to other Nectin-4-expressing malignancies including bladder cancer (搜索) and pancreatic cancer (搜索).